A case-control study of the association between anti-Müllerian hormone and ischemic stroke
Objective To investigate the association between plasma anti-Mullerian hormone(AMH)levels and ischemic stroke.Methods In this case-control study,93 ischemic stroke patients were randomly selected as the case group from a study on the prevention and treatment of metabolic syndrome,which was conducted in 2018-2019 in Changshu,Jiangsu Province,while 372 nonischemic stroke patients were selected as the control group according to the principle of 1∶4 matching.An enzyme-linked immunosorbent assay was used to measure plasma AMH levels.The conditional logistic regression model and restricted cubic spline were used to analyze the relationship between AMH levels and ischemic stroke.Results A total of 465 subjects with an average age of(68.7±7.4)years were included in this study,of whom 215(46.2％)were men and 250(53.8％)were women.According to our conditional Logistic regression analysis,the risk of ischemic stroke was reduced by 44％for every unit increase in the log-AMH level(OR=0.56,95％CI:0.37-0.85)in the overall population after multivariate adjustment.Compared with the tertile with the lowest AMH level,the risk of ischemic stroke in the tertile with the highest AMH level decreased significantly(OR=0.37,95％CI:0.19-0.69).When subgrouped by sex,the tertiles with the highest AMH levels were associated with a 66％lower risk of ischemic stroke in men(OR=0.34,95％CI:0.13-0.88)and a 64％lower risk of ischemic stroke in women(OR=0.36,95％CI:0.15-0.87),compared with the tertiles with the lowest AMH levels.The results of restricted cubic spline analysis showed that there was a linear dose-response relationship between plasma AMH levels and ischemic stroke both in the general population and in male or female population(P values for linear trends were 0.0002,0.008 and 0.007,respectively).Conclusions Higher plasma AMH levels decrease the risk of ischemic stroke with a dose-response pattern.
万方数据
维普
